What are treatment costs? 

The burden of schizophrenia includes direct costs, indirect costs, and intangible costs. Direct costs are estimated by the amount of services used and the price of treatment. Indirect costs are estimated by the averaged reduced future earnings of both patients and caregivers. Intangible costs are those that may be associated with the illness, such as trauma and depression. This topic presents evidence on direct pharmaceutical costs, including cost of drug treatments and related mental health care services.

What is the evidence for the costs of treating schizophrenia?

Moderate or moderate to low quality evidence suggests the cost of olanzapine is lower than haloperidol, but higher than risperidone. The cost of risperidone is also lower than fluphenazine, haloperidol, or other first generation antipsychotics. The cost of clozapine is lower than first generation antipsychotics including haloperidol and chlorpromazine, and mental healthcare and total healthcare costs of clozapine may be higher than risperidone. The cost of trifluoperazine alone, or in addition to individual psychotherapy, is lower than electroshock or milieu treatments.

October 2020

Last updated at: 5:10 am, 9th October 2020
To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.